Results 91 to 100 of about 16,388 (147)

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]

Rev Assoc Med Bras (1992)
Costa ALDS, Santos JED, Salgado Junior W, Bertoncini-Silva C, Bizari L, Moura GSPL, Liberatore Junior RDR, Zorzo RA, Suen VMM.   +8 more
europepmc   +1 more source

New-onset vitiligo following proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect. [PDF]

JAAD Case Rep
Umaña Mejia CA, Olvera Morales M, Jurado Orozco A, Burgos JD.   +3 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]

Rev Cardiovasc Med
Theofilis P, Vlachakis PK, Karakasis P, Iliakis P, Pamporis K, Oikonomou E, Dimitriadis K, Tsioufis K, Tousoulis D.   +8 more
europepmc   +1 more source

Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis. [PDF]

Medicine (Baltimore)
Du W, Li D, Li N, Zhang W, Wang J, Wang T, Zeng Y.   +6 more
europepmc   +1 more source

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial. [PDF]

BMJ Open
Chen Z, Ma S, Zhang J, Zhang R, Zhou M, Li C, Chen Y, Wang H, He Y, REPRESS trial investigator.   +9 more
europepmc   +1 more source

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer.

JAMA Netw Open
Lu CA, Jiang C, Wang AZ, Zhang T.
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease. [PDF]

Atheroscler Plus
Ugovšek S, Rehberger Likozar A, Levstek T, Trebušak Podkrajšek K, Zupan J, Marka F, Trimmel T, Brekalo M, Speidl W, Hohensinner P, Haider P, Šebeštjen M.   +11 more
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source